(DEDI) Dedicare (publ) - Ratings and Ratios

Dedicare AB (publ) is a specialized recruitment and staffing firm operating in the healthcare, life sciences, and social work sectors. The company provides recruitment services for doctors, nurses, social workers, sociologists, psychologists, preschool staff, and life science specialists across Sweden, Norway, Finland, the United Kingdom, and Denmark. Founded in 1995 and headquartered in Stockholm, Sweden, Dedicare has established itself as a key player in addressing workforce shortages in these critical industries. The company focuses on temporary and contract staffing solutions, enabling healthcare and social service organizations to maintain operational efficiency during periods of high demand or workforce turnover.

As of the latest data, Dedicare AB (publ) is traded under the ticker symbol DEDI on the Stockholm Stock Exchange (ST). The company operates within the Human Resource & Employment Services sub-industry and has a market capitalization of 564.20M SEK. Its current price-to-earnings (P/E) ratio stands at 8.56, with a price-to-book (P/B) ratio of 1.66 and a price-to-sales (P/S) ratio of 0.28. The return on equity (RoE) is reported at 15.74, indicating a strong return for shareholders. The average daily trading volume over the past 20 days is 35,603 shares, with a last price of 50.40 SEK. The stocks short-term trend indicators show a bearish outlook, with the last price below the 20-day (54.97), 50-day (58.15), and 200-day (62.63) simple moving averages (SMA). The average true range (ATR) is 2.21, reflecting moderate volatility.

3-Month Forecast: Based on the technical and fundamental data, Dedicare AB (publ) is expected to face headwinds in the near term. The stocks price is below its key SMA levels, suggesting bearish momentum. The low P/S ratio of 0.28 indicates undervaluation relative to its peers, but the high P/B ratio of 1.66 may signal overvaluation. With a strong RoE of 15.74, the companys profitability remains a positive factor. However, the technical outlook dominates, and the stock is likely to remain under pressure in the next three months, potentially testing support levels below 50 SEK. Investors should monitor volume and SMA trends for signs of a reversal.